New drug R&D

One of the most challenging tasks currently facing the human health care industry is to successfully discover, develop and commercialize new antibiotics with new modes of action. It is widely admitted that the current battery of antibiotics available to treat bacteria-caused diseases is running thin and one is very much struggling to cope satisfactorily with the occurrence of what is called “the new antibiotics resistant superbugs”.

The research activity in the antibiotics area has regained a vivid momentum through the use of new techniques such as Next Generation Sequencing (NGS). For instance, the NGS technology has been successfully used to accurately determine the antibiotic resistance genotypes of several bacteria such as Acinetobacter baumannii paving the way to the discovery of new methods to combat such organism. The bacteria can cause severe pneumonia and infections of the urinary tract, bloodstream and other parts of the body and is responsible for thousand of deaths annually in hospital settings.

Progenus proposes PCR and Next Generation Sequencing (NGS) and automatic genome annotation-based services:

  • Expertise in the thorough genomic and protein characterisation of antibiotic-resistant bacteria.
  • Assistance in the discovery of new and more potent antibiotics.